RELAPSED/REFRACTORY AUTOIMMUNE DISEASES
Clinical trials for RELAPSED/REFRACTORY AUTOIMMUNE DISEASES explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY AUTOIMMUNE DISEASES trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY AUTOIMMUNE DISEASES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immune cell therapy shows promise for autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment using CAR-T cells (a type of immune cell) for people with autoimmune diseases that have not responded to other therapies. The treatment targets CD19, a protein on certain immune cells, to help control the disease. The study will enroll 3 participa…
Matched conditions: RELAPSED/REFRACTORY AUTOIMMUNE DISEASES
Phase: NA • Sponsor: ShenZhen Cell Valley • Aim: Disease control
Last updated May 26, 2026 15:00 UTC
-
New cell therapy takes on tough autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment called LUCAR-G79 for people with autoimmune diseases like lupus that have not improved with standard care. The treatment uses specially modified cells to target and attack faulty immune cells. The main goals are to check safety and find the best d…
Matched conditions: RELAPSED/REFRACTORY AUTOIMMUNE DISEASES
Phase: PHASE1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated May 26, 2026 12:07 UTC
-
New cell therapy aims to tame stubborn autoimmune diseases
Disease control Recruiting nowThis early study tests a new treatment called LUCAR-DKS1 in 36 adults with autoimmune diseases that have not responded to standard therapies. The treatment uses specially designed immune cells to target and control the overactive immune system. The main goals are to check safety …
Matched conditions: RELAPSED/REFRACTORY AUTOIMMUNE DISEASES
Phase: EARLY_PHASE1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated May 26, 2026 12:05 UTC
-
New cell therapy AFN50 targets tough autoimmune conditions
Disease control Recruiting nowThis early-stage study tests a new injection called AFN50 in 18 adults with autoimmune diseases that haven't responded to standard treatments. The goal is to see if AFN50 is safe and can help control the disease by targeting the immune system's B cells. Participants will be close…
Matched conditions: RELAPSED/REFRACTORY AUTOIMMUNE DISEASES
Phase: EARLY_PHASE1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated May 26, 2026 12:02 UTC